Moreover, the shift toward biologics—complex molecules derived from living organisms—has added another layer of complexity to API manufacturing. Biopharmaceutical companies face unique challenges in the production, scaling, and regulatory approval of these products. As a result, manufacturers are investing more in research and development to innovate and streamline bioprocessing techniques.